Encompass Health: 24-Bed Boxes, a Jammed Billing Queue, and an Overhang That Went Quiet

Encompass Health's third quarter is the kind of print that reads as consensus and trades as relief. Revenue rose 8.9%, adjusted EBITDA 15.5%, adjusted EPS 23.6%, and management raised full-year guidance for at least the third time in 2026 — to $6.45–6.5B of revenue, $1.395–1.415B of adjusted EBITDA, and $6.23–6.37 of adjusted EPS. The stock has run roughly 29% over the last seventeen weeks and sits within 3% of its period high, which matters because it follows a 21-week, 21% slide. That round trip is the story: a de-rating on regulatory fear, and a re-rating as the fear got industrialised into process.

The overhang that stopped being an overhang

Three anxieties dominated 2026 for this name: the TEAM mandatory-bundling model, Medicare Advantage pre-authorization denials, and CMS's Review Choice Demonstration audits. All three show up in this call — none of them as threats.

On TEAM, the February call was defensive; Pat Tuer then said flatly “there's been no impact of team associated diagnoses categories within our team impacted markets” — Patrick Tuer, Chief Operating Officer or Senior Executive · 2026-02-06. In this quarter TEAM appears only as a mix footnote — knee and hip replacement down 3.6%, displaced by lower acuity backfill with stroke, brain injury and trauma patients. On Medicare Advantage, the admit-and-appeal pilot has become policy: 294 claims, 87% overturned in Encompass's favour, 81% before ever reaching an ALJ; pilot hospitals expanded from 9 to 13, and the programme is being taught to every hospital for stroke, with brain injury and spine next. That converts a payer behaviour problem into an administrative competency.

Then there is RCD. In August, Doug Coltharp told investors “we're not currently aware of plans by CMS to extend RCD into any other states at this time” — Douglas Coltharp, Chief Financial Officer · 2026-08-06. On this call, 75 more hospitals enter Jurisdiction JJ on January 1, with Cycle 1 mandating 100% prepayment claim review and a 100% nobody-gets-out-of-it rule.

The expansion into Jurisdiction JJ is going to increase the volume that they're going to have to process by more than 10x… that's going to be a real burden on Palmetto, and we just want a greater understanding as to how they're going to be able to process that.

The mitigant is arithmetic: exceed the 80% target affirmation rate in Cycle 1 and from July 1 a hospital can drop to a 5% spot check — which Texas's 24 hospitals just did after performing well. Management is effectively arguing bad debt reverts to its 2%–2.5% range, with any noise contained to the first half. That is a forecast, not a fact, but it is a well-reasoned one.

The 24-bed growth machine

The genuinely new content is the small-format hospital, and this quarter it got numbers attached. De novos run at roughly $1.25M per bed for a mid-teens IRR; bed additions to existing hospitals at $850k per bed and 25%+ IRRs. Small format lands in between, as Coltharp laid out: “we're estimating the cost per bed on those will be right at $1 million, and we're targeting an IRR of about 20%” — Douglas Coltharp, Executive · 2026-10-29. The operating leverage is the point — sharing admin with a host hospital lets a small format run employees-per-occupied-bed below 3x against a corporate norm just under 3.4x.

Our operators and development team have identified about 200 locations where this potentially could happen… I think we would all be collectively disappointed if we're opening less than 6 of those a year by that point.

One opens in late 2027, the delay being licensing and permitting novelty rather than capital or contractors — and North Carolina's CON repeal, effective October 1, is the natural runway: 15 markets prioritised, 6 parcels under contract, one hospital in the state today. This is a small format strategy with a cost per bed discipline attached, which is a different thing from the concept that has been floating around for four quarters.

Which brings the tension: this is a capex story wearing an EBITDA story's clothes. capital expenditure ran $220M in the June quarter, up 40% year over year against revenue of $1.6B, up 10%. That is a capex intensity near 14% of revenue, and the May guidance that capex would peak near 15% then recede to 10%–12% now looks optimistic on timing, because Coltharp conceded “we're likely to see our discretionary CapEx begin to increase” — Douglas Coltharp, Executive · 2026-10-29. Even so, at 1.8x net leverage, $870M of revolver capacity, $203.7M of year-to-date buybacks and an interest coverage ratio that has climbed to 8.0x, the funding is not in question.

Where the quarter actually wobbled

Two items deserve more airtime than they got. First, Bad debt expense at 2.7% of revenue — about 70bp above the normalised band — and two-thirds of it was Encompass's own doing. In Q2 the company migrated patient billing off a sunsetting legacy system called Patcom onto Oracle's module, and: “the pending claims that were left in the legacy system required a more manual processing… as these claims were pending, they became subject to our aging-based reserve methodology” — Douglas Coltharp, Executive · 2026-10-29. Medicare was cleared by quarter-end; managed care and MA, with their higher co-pays and higher bad debt, were not. It is a one-off — but it is the second system conversion in eighteen months to cost real dollars, and the market should price the pattern, not just the quarter.

Second, supplemental payment volatility. Florida's FY2026 state-directed programme is still pending CMS approval, so $9.2M of accrued supplemental payments and $3.4M of provider tax expense were reversed. Net provider tax contribution for 2026 now guides to about $3M versus a prior ~$10M expectation. If Florida clears in Q4, an $8M EBITDA benefit lands — a swing item that has nothing to do with running hospitals.

And the quiet one: the labour flywheel is maturing. Premium labor fell again, to $23.1M, the sixteenth consecutive year-over-year decline, with contract FTEs at 0.9% of the workforce — the lowest since Q4 2020. But Coltharp has been pre-announcing the end of that tailwind since August, when he said “we've kind of hit the point of diminishing returns” — Douglas Coltharp, Chief Financial Officer · 2026-08-06, and he repeated it here. Tellingly, the company's own career ladder language, a centrepiece three quarters ago, now shows up as a cost headwind and an anniversary item — the keyword's own momentum has rolled over. The earnings engine must hand off from labour efficiency to acuity-driven pricing, and pricing is about to lap a 4.1% comp with a widening MA discount.

What the tape is voting on

Nothing here rhymes with the market's obsession. The global advancers are semiconductors and AI data centers; healthcare facilities trade on their own cash flows. Encompass's multiple had already de-rated hard through the TEAM/MA scare — price to operating income at 9.8x, down 32% year over year — before this run restored it. The right read is that this is an idiosyncratic re-rating on removed uncertainty plus a new capacity modality, not a sector wave, and the risk to it is not demand. It is whether a company that just jammed a billing queue can execute a national licensing build-out while absorbing a 10x volume increase in audit prepayment review, all in the same twelve months.